UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 13, 2017
UNIVERSAL HOSPITAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-20086 |
|
41-0760940 |
(State or other jurisdiction of |
|
(Commission |
|
(IRS Employer |
incorporation) |
|
File Number) |
|
Identification No.) |
6625 West 78th Street, Suite 300
Minneapolis, Minnesota 55439-2604
(Address of principal executive offices)
(Zip Code)
952-893-3200
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 13, 2017 Universal Hospital Services, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
ITEM 7.01 REGULATION FD DISCLOSURE
Attached as Exhibit 99.2 to this report, and incorporated herein by reference, is a copy of the slide presentation for the investor conference call with management scheduled for November 14, 2017, to discuss Universal Hospital Services, Inc.s announced results for the quarter ended September 30, 2017.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) |
|
Exhibits |
99.1 |
|
Press release issued by Universal Hospital Services, Inc. on November 13, 2017 |
99.2 |
|
EXHIBIT INDEX
Exhibit Number |
|
Description |
99.1 |
|
Press release issued by Universal Hospital Services, Inc. on November 13, 2017 |
99.2 |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, Universal Hospital Services, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 13, 2017 |
UNIVERSAL HOSPITAL SERVICES, INC. | |
|
| |
|
By |
/S/ James B. Pekarek |
|
James B. Pekarek | |
|
Executive Vice President and Chief Financial Officer |
Corporate Office 6625 West 78th Street, Suite 300 Minneapolis, MN 55439 Phone: 952.893.3200 Fax: 952.893.0704 www.uhs.com |
CONTACT: James Pekarek;
Executive Vice President and Chief Financial Officer
Universal Hospital Services, Inc.
(952) 607-3054
UNIVERSAL HOSPITAL SERVICES REPORTS 2017 THIRD QUARTER RESULTS
Minneapolis, Minn.(BUSINESS WIRE) November 13, 2017 Universal Hospital Services, Inc. (UHS), today announced financial results for the quarter ended September 30, 2017.
Total revenues for the three months ended September 30, 2017, were $123.8 million, representing a $5.9 million or 4.9 percent increase from total revenues of $117.9 million for the same period of 2016. Total revenues for the nine months ended September 30, 2017 were $382.6 million representing a $24.9 million or 7.0 percent increase from total revenues of $357.7 million for the same period of 2016.
Adjusted EBITDA for the three months ended September 30, 2017, was $33.2 million, a $0.7 million or 2.2 percent increase from adjusted EBITDA of $32.5 million for the same period of 2016. Adjusted EBITDA for the nine months ended September 30, 2017, was $101.9 million, a $5.6 million or 5.8 percent increase from adjusted EBITDA of $96.3 million for the same period of 2016.
Conference Call Dial-in Information
UHS will hold a conference call to discuss 2017 third quarter results on Tuesday, November 14, at 9 a.m. Eastern Time (8 a.m. Central Time).
To participate, call (855) 539-7565 and advise the operator that you would like to join the Universal Hospital Services 2017 Third Quarter Earnings Conference Call. A recording of this call will be available from 12 p.m. Eastern Time on November 14, through 11:59 p.m. Eastern Time on December 13, and can be accessed by calling (855) 859-2056 and using the conference ID 85101060.
UHS will also use a slide presentation to facilitate the conference call discussion. A copy of the presentation may be obtained via the companys website at www.uhs.com. Select Investors then Presentations.
Adjusted EBITDA Reconciliation
Adjusted EBITDA is defined by UHS as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), and excludes non-cash share-based compensation expense, management, board and other non-recurring gain, expenses, or loss, which may not be calculated consistently among other companies applying similar reporting measures. EBITDA and Adjusted EBITDA are not intended to represent an alternative to operating income or cash flows from operating, financing or investing activities (as determined in accordance with generally accepted accounting principles (GAAP)) as a measure of performance, and are not representative of funds available for discretionary use due to UHS financing obligations. EBITDA is included because it is a widely accepted financial indicator used by certain investors and financial analysts to assess and compare companies and is an integral part of UHS debt covenant calculations. Adjusted EBITDA is included because UHS financial guidance and certain compensation plans are based upon this measure. Management believes that Adjusted EBITDA provides an important perspective on the companys ability to service its long-term obligations, the companys ability to fund continuing growth, and the companys ability to continue as a going concern. A reconciliation of consolidated net income (loss) to EBITDA and Adjusted EBITDA is included below.
EDITDA Reconciliation (YTD)
|
|
3rd Quarter |
|
September YTD |
|
LTM |
| |||||||||
(In millions) |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
|
2017 |
| |||||
Net loss attributable to UHS |
|
$ |
(3.2 |
) |
$ |
(3.7 |
) |
$ |
(7.6 |
) |
$ |
(9.1 |
) |
$ |
(12.3 |
) |
Interest expense |
|
13.3 |
|
13.1 |
|
39.8 |
|
39.2 |
|
52.9 |
| |||||
Provision for income taxes |
|
0.4 |
|
0.3 |
|
0.9 |
|
0.7 |
|
1.1 |
| |||||
Depreciation and amortization |
|
19.5 |
|
20.9 |
|
60.5 |
|
63.3 |
|
81.6 |
| |||||
EBITDA |
|
30.0 |
|
30.6 |
|
93.6 |
|
94.1 |
|
123.3 |
| |||||
Gain on Settlement |
|
|
|
|
|
|
|
(2.8 |
) |
(0.3 |
) | |||||
Management, board & other |
|
2.4 |
|
1.1 |
|
6.0 |
|
2.7 |
|
8.5 |
| |||||
Stock expense |
|
0.8 |
|
0.8 |
|
2.3 |
|
2.3 |
|
3.1 |
| |||||
Adjusted EBITDA |
|
$ |
33.2 |
|
$ |
32.5 |
|
$ |
101.9 |
|
$ |
96.3 |
|
$ |
134.5 |
|
About Universal Hospital Services, Inc.
Universal Hospital Services, Inc. is a leading nationwide provider of health care technology management and service solutions to the health care industry. UHS owns or manages more than 700,000 units of medical equipment for more than 7,000 national, regional and local acute care hospitals and alternate site providers across the U.S. For more than 75 years, UHS has delivered medical equipment management and service solutions that help clients reduce costs, increase operating efficiencies, improve caregiver satisfaction and support optimal patient outcomes.
Universal Hospital Services, Inc.
6625 West 78th Street, Suite 300
Minneapolis, MN 55439
952-893-3200
www.uhs.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Universal Hospital Services, Inc., believes statements in this presentation looking forward in time involve risks and uncertainties. The following factors, among others, could adversely affect our business, operations and financial condition causing our actual results to differ materially from those expressed in any forward-looking statements: our history of net losses and substantial interest expense; our need for substantial cash to operate and expand our business as planned; our substantial outstanding debt and debt service obligations; restrictions imposed by the terms of our debt; a decrease in the number of patients our customers are serving; our ability to effect change in the manner in which health care providers traditionally procure medical equipment; the absence of long-term commitments with customers; our ability to renew contracts with group purchasing organizations and integrated delivery networks; changes in reimbursement rates and policies by third-party payors; the impact of health care reform initiatives; the impact of significant regulation of the health care industry and the need to comply with those regulations; the effect of prolonged negative changes in domestic and global economic conditions; difficulties or delays in our continued expansion into certain of our businesses/geographic markets and developments of new businesses/geographic markets; additional credit risks in increasing business with home care providers and nursing homes, impacts of equipment product recalls or obsolescence; increases in vendor costs that cannot be passed through to our customers; and other Risk Factors as detailed in our annual report on Form 10-K for the year ended December 31, 2016, as well as our other filings with the Securities and Exchange Commission.
Presented by Tom Leonard, CEO November 14, 2017 Universal Hospital Services Q3 Earnings Teleconference
Forward Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Universal Hospital Services, Inc. believes statements in this presentation looking forward in time involve risks and uncertainties based on managements current views and assumptions. Actual events may differ materially. Please refer to the cautionary statement regarding forward-looking statements and risk factors that appear in the Companys Annual Report on Form 10-K for the year ended December 31, 2016, and other filings with the SEC, which can be accessed at www.UHS.com under Investors. This presentation contains non-GAAP measures as defined by SEC rules. Reconciliations of these measures to the most directly comparable GAAP measures are contained in the appendix.
CEO remarks
Financial Review
Selected Financial Data Note: Numbers referenced in the % Chg column are favorable when positive and unfavorable when negative. This applies to all slides reflected herein. Refer to Appendix for reconciliation of Adjusted EBITDA and Accrual CAPEX. (In millions) LTM 2017 2016 % Chg 2017 2016 % Chg 2017 Consolidated Revenues 123.8 $ 117.9 $ 4.9% 382.6 $ 357.7 $ 7.0% 504.4 $ Gross Margin 39.4 38.5 2.2% 127.1 117.1 8.5% 166.9 % of Revenue 31.9% 32.7% 33.3% 32.7% 33.1% Adjusted SG&A 23.6 24.3 2.9% 78.0 75.5 -3.4% 103.5 % of Revenue 19.0% 20.6% 20.4% 21.1% 20.5% Adjusted EBIT(A) 15.8 14.1 11.4% 48.8 41.4 17.8% 63.1 Depreciation 17.4 18.4 53.1 54.9 71.4 Adjusted EBITDA 33.2 $ 32.5 $ 2.2% 101.9 $ 96.3 $ 5.8% 134.5 $ % of Revenue 26.8% 27.6% 26.6% 26.9% 26.7% Accrual CAPEX 13.8 11.1 28.2 29.9 55.8 Adjusted EBITDA - Accrual CAPEX 19.4 $ 21.4 $ -8.8% 73.7 $ 66.4 $ 10.9% 78.7 $ 3rd Quarter September YTD
Trend Analysis Segment revenue declined 3.7% for the quarter as we continue to diversify away from our capital intensive Asset360 business and reduce capital sales (-$1.7M). Supplemental rental revenue declined from lower demand due to weak recent inpatient census trend. Gross margin rate declined due to the unfavorable mix shift resulting from lower rental volume in the quarter. Medical Equipment Solutions SUPPLEMENTAL & PEAK NEEDS USAGE SOLUTIONS CUSTOMIZED EQUIPMENT AGREEMENTS SOLUTIONS 360 ON-SITE MANAGED SOLUTIONS SPECIALTY MEDICAL EQUIPMENT SALES, DISTRIBUTION AND DISPOSAL SOLUTIONS (In millions) LTM 2017 2016 % Chg 2017 2016 % Chg 2017 Revenues 70.7 $ 73.5 $ -3.7% 223.8 $ 228.6 $ -2.1% 298.9 $ Gross Margin 24.8 26.3 -5.9% 83.9 81.6 2.8% 111.5 % of Revenue 35.0% 35.8% 37.5% 35.7% 37.3% September YTD 3rd Quarter
Trend Analysis Revenue growth for the quarter of 26.9% included the contribution from our Q4 2016 acquisition of RES and organic growth of 9%. Growth in both solutions driven by our continued market success selling supplemental and full-outsource clinical engineering solutions. Gross margin rate improvements driven by favorable mix of higher modalities. Clinical Engineering Solutions SUPPLEMENTAL MAINTENANCE AND REPAIR SOLUTIONS ON-SITE MANAGED SOLUTIONS MANUFACTURER SERVICES SOLUTIONS (In millions) LTM 2017 2016 % Chg 2017 2016 % Chg 2017 Revenues 34.2 $ 26.9 $ 26.9% 103.9 $ 78.0 $ 33.3% 133.6 $ Gross Margin 7.4 5.6 31.1% 22.8 16.0 42.2% 28.8 % of Revenue 21.7% 21.0% 21.9% 20.5% 21.6% 3rd Quarter September YTD
Trend Analysis Revenue growth of 7.6% in Q3 reflects share capture. Gross margin rate improvement in Q3 of 70bps was driven by volume growth, favorable mix shift to higher margin modalities, and progress on our strategy to drive increased geographic market density near our in-market operations centers. Surgical Services ON-DEMAND AND SCHEDULED USAGE SOLUTIONS ON-SITE MANAGED SOLUTIONS (In millions) LTM 2017 2016 % Chg 2017 2016 % Chg 2017 Revenues 18.9 $ 17.6 $ 7.6% 54.9 $ 51.1 $ 7.5% 71.9 $ Gross Margin 7.2 6.6 9.6% 20.5 19.5 5.1% 26.6 % of Revenue 38.1% 37.4% 37.3% 38.2% 37.0% 3rd Quarter September YTD
Capital Structure/Liquidity (In millions) 9/30/2017 12/31/2016 Original Notes - 7.625% 425.0 425.0 Add-on Notes - 7.625% 220.0 220.0 Credit Facility 63.0 45.7 Consolidated Capital Leases 17.1 17.1 Subtotal Debt 725.1 707.8 Add: Accrued Interest 6.4 18.7 Total Debt and Interest 731.5 726.5 Memo LTM Adjusted EBITDA 134.5 $ 128.9 $ Leverage* 5.4 5.6 *Excludes unamortized bond premium of $6.2 and $7.6 for 2017 and 2016. Excludes deferred financing costs of $6.4M and $8.2M for 2017 and 2016. Capital Structure (In millions) 2017 Credit Facility 235.0 $ Borrowing Base 161.4 Borrowings/LOC 67.9 Available Liquidity 93.5 $ Memo Revolver maturity - May 2020 Original and Add-on Notes maturity -August 2020 Liquidity Remains Strong Liquidity
Street Guidance for 2017 (In millions) 2016 Actual 2017 Prior Guidance 2017 Current Guidance Adjusted EBITDA $128.9 $135 - $140 $135 - $139 Accrual CAPEX $57 $50 - $60 $50 - $55 Year-end Leverage 5.6x 5.2x 5.5x 5.2x 5.5x We have lowered the top end of our Adjusted EBITDA guidance, which incorporates our current forecasted impact of approximately $1M due to hurricanes Harvey and Irma. We have also lowered the top end of our Accrual CAPEX forecast, reflecting our continued progress in reducing the capital intensity of our business model.
Appendix EBITDA Reconciliation 2017 & 2016 SG&A Reconciliation Depreciation and Amortization Reconciliation Accrual CAPEX Reconciliation
EBITDA Reconciliation Adjusted EBITDA Reconciliation. Adjusted EBITDA is defined by UHS as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), and excludes non-cash share-based compensation expense, management, board and other non-recurring gain, expenses, or loss. In addition to using Adjusted EBITDA internally as a measure of operational performance, we disclose Adjusted EBITDA externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. Management also understands that some industry analysts and investors consider Adjusted EBITDA as a supplementary non-GAAP financial measure useful in analyzing a companys ability to service debt. Adjusted EBITDA, however, is not a measure of financial performance under Generally Accepted Accounting Principals (GAAP) and should not be considered as an alternative to, or more meaningful than, net income as a measure of operating performance or to cash flows from operating, investing or financing activities or as a measure of liquidity. Since Adjusted EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying interpretations and calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Adjusted EBITDA does not represent an amount of funds that is available for managements discretionary use. A reconciliation of consolidated net income (loss) to EBITDA and Adjusted EBITDA is included below. (In millions) LTM 2017 2016 2017 2016 2017 Net loss attributable to UHS (3.2) $ (3.7) $ (7.6) $ (9.1) $ (12.3) $ Interest expense 13.3 13.1 39.8 39.2 52.9 Provision for income taxes 0.4 0.3 0.9 0.7 1.1 Depreciation and amortization 19.5 20.9 60.5 63.3 81.6 EBITDA 30.0 30.6 93.6 94.1 123.3 Gain on Settlement - - - (2.8) (0.3) Management, board & other 2.4 1.1 6.0 2.7 8.5 Stock expense 0.8 0.8 2.3 2.3 3.1 Adjusted EBITDA 33.2 $ 32.5 $ 101.9 $ 96.3 $ 134.5 $ September YTD 3rd Quarter
SG&A Reconciliation (In millions) LTM 2017 2016 2017 2016 2017 SG&A per GAAP to Adjusted SG&A SG&A per GAAP 28.8 28.7 93.8 88.9 125.1 Management, board, & other (2.4) (1.1) (6.0) (2.7) (8.5) Stock expense (0.8) (0.8) (2.3) (2.3) (3.1) Amortization (2.1) (2.6) (7.4) (8.4) (10.1) Adjusted SG&A 23.6 $ 24.3 $ 78.0 $ 75.5 $ 103.5 $ 3rd Quarter September YTD
Depreciation & Amortization Reconciliations (In millions) LTM 2017 2016 2017 2016 2017 Historical Medical Equipment Solutions Depreciation 14.0 $ 15.1 $ 43.0 $ 45.6 $ 58.1 $ Asset Impairment Charge - - - - - Total Medical Equipment Solutions Depreciation 14.0 15.1 43.0 45.6 58.1 Historical Clinical Engineering Solutions Depreciation 0.3 0.2 0.8 0.7 1.0 Total Clinical Engineering Solutions Depreciation 0.3 0.2 0.8 0.7 1.0 Historical Surgical Services Depreciation 2.1 1.9 6.1 5.2 8.0 ASC 805 Surgical Services Depreciation - - - 0.1 - Total Surgical Services Depreciation 2.1 1.9 6.1 5.3 8.0 Historical Gross Margin Depreciation 16.4 17.2 49.9 51.5 67.1 Gross Margin ASC 805 Depreciation - - - 0.1 - Total Gross Margin Depreciation 16.4 17.2 49.9 51.6 67.1 Historical Selling, General, and Admin Depreciation 1.0 1.2 3.2 3.3 4.4 Total Selling, General, and Admin Depreciation 1.0 1.2 3.2 3.3 4.4 Total Depreciation 17.4 $ 18.4 $ 53.1 $ 54.9 $ 71.4 $ ASC 805 Selling, General, and Admin Amortization 2.1 2.6 7.4 8.4 10.1 Total ASC 805 Selling, General, and Admin Amortization 2.1 2.6 7.4 8.4 10.1 Total Depreciation and Amortization 19.5 $ 20.9 $ 60.5 $ 63.3 $ 81.6 $ September YTD 3rd Quarter
Accrual CAPEX Reconciliation
Thank you.
MM:OY&M01&\D&H_&&GH8'>7 0&V_OGB"6E@D';.@2;*@&;-"&S:(16\-_4.=_
M'T%.8 .(;MV^?1L8+MRV;@C#=2LG\* Y<^7"18PH+Z(]>^8R8K2W3M['C_;N
MK?.8<5W)C/4.'/_*R.1O#-5V%'8XD5 0&3
M=:+5N7R9RJT+B;8+^9A/O!A6&.LEZY'6NLK.C'J')!H,
I05;="J&T6$
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MW08B$N5@C[RQGW)4:T)2BIG,3HJ/
M?1PG2U&3H81&.)R9*:9/16/I>WZX(\L%<1M9L>F35@@ELOGT24YR(HJ@%D4/
M 35F0KK7A)!4MJ02J3E60])2U<@H.-4MQ?!HXXK;5*<[W0FK=&2(,;DJD3UN
M!!R(
/#Z[D\"%%;*\ ^KTC.D.8UT#&HYVEN&\T0VT0[-W
ME-:+8C -KDK?!=3
#<+_^QQBC:7WUU\_)6WK(I4>>N0M3-[3E5.-MEW[UMZVV>P'P7KCQS6M<
M(QO6 .QBP2$.P6!!C>(\IV#:4 YTD(,<;1 C.L]!S\2DTS!B<.,D&R,?>]K3
MJJ<$J"C[N$I4E7A2(%//*@J&W!H QRP,3W&564K
M57%;,X;QAA6LH!(:44:<[F3